Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383872 · ClinicalTrials.gov registry record · NA
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 71
- Enrollment target
NCT05383872 is a NA study that has completed, run by InSightec. The registered enrollment target is 71 participants.
The verdict
NCT05383872, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Interventions
- DEVICE Focused Ultrasound (Exablate Model 4000)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2025-03-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05383872
The ClinicalTrials.gov registry entry for NCT05383872 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Focused Ultrasound (Exablate Model 4000) is the first listed.
NCT05383872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05383872 about?
NCT05383872 is a clinical study titled "Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors". The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
What is the current status of trial NCT05383872?
This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2022-08-08. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05383872?
The interventions under investigation include: Focused Ultrasound (Exablate Model 4000) (DEVICE).
Who is sponsoring clinical trial NCT05383872?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.